The long acting monoclonal antibody nirsevimab (marketed as Beyfortus) reduced respiratory syncytial virus associated hospital admissions in infants […]
The long acting monoclonal antibody nirsevimab (marketed as Beyfortus) reduced respiratory syncytial virus associated hospital admissions in infants […]